Transgene S.A.
Other OTCTotal Valuation
Transgene S.A. carries a market capitalization of 122.57M, placing it among publicly traded companies globally. Its enterprise value stands at -4.48M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 122.57M |
| Enterprise Value | -4.48M |
Financial Position
Transgene S.A. maintains a current ratio of 1.58, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.58 |
| Quick Ratio | 1.02 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -76.58 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -176,764.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Transgene S.A.'s stock has gained approximately 21.42857% over the past 52 weeks. The 50-day moving average sits at 1.00, while the 200-day moving average is 0.79.
| Beta (5Y) | N/A |
| 52-Week Price Change | 21.42857% |
| 50-Day Moving Average | 1.00 |
| 200-Day Moving Average | 0.79 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Transgene S.A. generated 3.65M in revenue and converted that into -19.12M in net income, yielding earnings per share of -1.84. EBITDA reached -26.55M, while operating income came in at -26.55M.
| Revenue | 3.65M |
| Gross Profit | N/A |
| Operating Income | -26.55M |
| Pretax Income | -4.88M |
| Net Income | -19.12M |
| EBITDA | -26.55M |
| EBIT | -26.55M |
| Earnings Per Share (EPS) | -1.84 |
Balance Sheet
Total book value stands at -215.95M, with working capital of 2.55M providing operational flexibility.
| Cash & Cash Equivalents | 4.48M |
| Total Debt | N/A |
| Net Debt | -4.48M |
| Equity (Book Value) | -215.95M |
| Book Value Per Share | -20.75 |
| Working Capital | 2.55M |
Margins
Transgene S.A. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -727.57 and net profit margin of -524.07 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -727.57 |
| Pretax Margin | -133.71 |
| Profit Margin | -524.07 |
| EBITDA Margin | -727.57 |
Stock Splits
Transgene S.A.'s most recent stock split took place on June 18, 2019 with a 39:40 split ratio.
| Last Split Date | 6/18/2019 |
| Split Ratio | 39:40 |
Scores
Transgene S.A. posts an Altman Z-Score of -25.31, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -25.31 |